Tarceva Survival Advantage In Pancreatic Cancer Not "Clinically Meaningful," FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency's briefing documents for Tarceva's Oncologic Drugs Advisory Committee review raise concerns about rates of serious adverse events and treatment-related fatalities.